Epigenetic Changes at the Birc5 Promoter Induced by YM155 in Synovial Sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• YM155 is an apoptosis-inducing anti-cancer therapy investigated in 11 clinical trials.
• The precise mechanism of YM155, particularly its effect on survivin (Birc5) expression, is not fully understood.
• Synovial sarcoma, a rare malignancy, exhibits high survivin protein levels, suggesting it as a potential target.

Purpose of the Study:

• To evaluate YM155 as a therapeutic option for synovial sarcoma.
• To elucidate the molecular mechanism by which YM155 affects survivin expression in synovial sarcoma.

Main Methods:

• YM155 treatment was applied to human synovial sarcoma cell lines and a genetically engineered mouse model.
• Chromatin immunoprecipitation (ChIP)-qPCR was used to analyze histone modifications near the Birc5 promoter.
• Caspase activity was assessed to determine the extent of apoptosis.

Main Results:

• YM155 demonstrated nanomolar potency against synovial sarcoma cell lines.
• Mice treated with YM155 showed a 50% reduction in tumor volume compared to controls.
• YM155 treatment altered H3K27me3 and H3K27ac epigenetic marks at the Birc5 promoter, leading to decreased Birc5/survivin expression and increased caspase 3/7/8 activity, ultimately causing cell death.

Conclusions:

• YM155 is a potent therapeutic agent for synovial sarcoma, significantly reducing tumor growth.
• The mechanism involves YM155-induced epigenetic changes at the Birc5 promoter, decreasing survivin expression.
• This leads to apoptosis and provides a rationale for YM155's clinical application in synovial sarcoma.